Jiangsu Dongkekangde Pharmaceutical Co., Ltd. Accredited as National High-Tech Enterprise

On November 19, the Office of the Leading Group for the National High-Tech Enterprise Certification Management released the Public Announcement on Filing the Second Batch of High-Tech Enterprises Certified by Jiangsu Provincial Certification Authority in 2024. Jiangsu Dongkekangde Pharmaceutical Co., Ltd. (hereinafter referred to as "Dongkekangde"), a wholly-owned subsidiary of Caremo, has successfully obtained the National High-Tech Enterprise certification.

The National High-Tech Enterprise certification requires applicants to meet stringent criteria, including: ownership of core intellectual property rights supporting their primary products/services, alignment of core technologies with the National Key Supported High-Tech Fields, a minimum 60% revenue contribution from high-tech products/services in the preceding fiscal year, and compliance with innovation capability evaluation standards.

This accreditation recognizes Dongkekangde's achievements in R&D investment, talent structure, and innovation capabilities, signifying its elevated level of R&D strength and operational standardization. It marks a critical milestone in the company's journey toward higher-tier development.

Established in June 2021 as a wholly-owned subsidiary of Nanjing Caremo Biomedical Co., Ltd., Dongkekangde offers comprehensive one-stop services spanning the entire lifecycle of Marketing Authorization Holder (MAH) projects. Its services encompass CMC development, supplier management/audits, CMO selection/audits, technology transfer, clinical auditing, contract manufacturing supervision, sales/usage management, traceability management, and pharmacovigilance. From project initiation to commercialization, Dongkekangde delivers tailored MAH solutions to meet diverse client needs. The company obtained its Drug production license (Category B) in September 2022.

Moving forward, Dongkekangde will continue to uphold an open and collaborative approach, partnering with domestic and international pharmaceutical and biotech companies to establish itself as an exemplar of high-tech, high-growth, and high-value enterprises, contributing to the accelerated development of China's pharmaceutical industry.